Skip to content

In the BioHarmony Drug Report Database

Margetuximab

Margenza (margetuximab) is an antibody pharmaceutical. Margetuximab was first approved as Margenza on 2020-12-16. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
Trade Name Margenza
Common Name Margetuximab
Indication
Drug Class Monoclonal antibodies: chimeric, tumors as target
Margetuximab
Get full access now